RCUS - Arcus Biosciences Inc logo

Arcus Biosciences Inc

RCUS

Arcus Biosciences develops targeted cancer immunotherapies, focusing on HIF-2a, TIGIT, and PD-1 inhibitors, among others. Its pipeline includes therapies for kidney, lung, and gastrointestinal cancers, enhanced through strategic collaborations in drug development.

โš•๏ธ Healthcare NYSE Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$525today

Score Overview

1 Year
Score
Net Growth-28.05%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-52.63%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score1.7
Net Growth-8x
Net Trend20%
Net Income Consistencyโ€”
Rev Growth-69.45%
Rev Trend40%
Revenue Consistencyโ€”
All Time
Score
Net Growth-7x
Net Trend25%
Net Income Consistency
Rev Growth14x
Rev Trend63%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Arcus Biosciences Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. RCUS does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 18.54โ€”
1 Year2025-10-23
$ 16.7810.49%
5 Years2021-10-22
$ 35.33-47.52%
All Time2018-03-15
$ 17.009.06%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 117M-$ 452M$ 702M
2025$ 247M-$ 353M$ 981M
2024$ 258M-$ 283M$ 978M
2023$ 117M-$ 307M$ 759M
2022$ 112M-$ 267M$ 1.00B
2021$ 383M$ 53M$ 499M
2020$ 78M-$ 123M$ 728M
2019$ 15M-$ 75M$ 188M
IPO2018$ 8M-$ 49M$ 256M
RCUS - Arcus Biosciences Inc logo

Arcus Biosciences Inc fundamental performance

Across Arcus Biosciences Inc's full reported history, from 2018 to 2025, revenue grew from $ 8M to $ 247M and net income went from -$ 49M to -$ 353M. Revenue increased in 63% of the years measured; net income in 25%.

Arcus Biosciences Inc currently holds a 5-year HDB Score of 1.7 out of 10. How the HDB Score is calculated.

Membership

Explore RCUS with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies